Navigation Links
WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
Date:10/14/2008

our internal capacity.

These forward-looking statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Our preliminary Q3 2008 operating results may change as a result of final management review, review by outside auditors, finalization of share-based compensation expenses and closing adjustments for the quarter. Also the uncertainty in the global economy may adversely impact our business and R&D outsourcing trends; and our smaller biotech customers may continue to face funding and other spending difficulties for longer than anticipated. We may be unable to successfully expand our capabilities to meet client needs. In addition other factors that could cause our actual results to differ from what we currently anticipate include our limited operating history; failure to generate sufficient future cash flows or secure any required future financing on acceptable terms or at all; failure to retain key personnel; effective integration of products and services from AppTec; our reliance on a limited number of customers to continue to account for a high percentage of our revenues; risk of payment failure by any of our large customers, which could significantly harm our cash flows and profitability; dependency upon the continued service of our senior management and key scientific personnel and ability to retain our existing customers or expand our customer base. The financial information contained in this release should be read in conjunction with the consolidated and pro forma financial statements and notes thereto included in our 2007 Annual Report on Form 20-F filed with available on the Securities and Exchange Commission's website at

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
2. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
3. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
4. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
5. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
6. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
7. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
8. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
9. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
10. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
11. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...cative new study, a University of Utah scientist a...jor cause of global warming cannot be stabilized ...ilds the equivalent of one new nuclear power plant... be any substantial near-term departure from recen...on rates," says the new paper by Tim Garrett, an a...
(Date:11/23/2009)...unication, computation and more powerful ways to e...antum states as carriers of information is an extr...hown, mathematically, how to gently tease out unwa... the information intact. Their work is reported in...d highlighted with a Viewpoint in Physics ( http...
(Date:11/23/2009)...e-FirstCall/--PDLBioPharma,Inc.(PDL)(Nasdaq: PDLI ...2009astheex-dividenddateforits$200millionspecialdi...transactioncompletedonNovember2,2009.Thedividendwi...ontherecorddate,December1,2009.NASDAQhassettheappr...fcommonstockforpurposesoftheex-dividenddateonNovem...
(Date:11/23/2009)...tCall/--NeogenCorporation(Nasdaq: NEOG )announcedt...sBoardofDirectorsatthecompany,srecentannualmeeting...xperienceinthefood,agriculture,andtradeindustriesa...leconomicsatVirginiaTechUniversity.FromJanuary2006...enegotiatorwiththerankofambassador. ,, "Sinceou...
Breaking Biology Technology:Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2Richard T. Crowder Joins Neogen's Board of Directors 2
...erMune, Inc.,(Nasdaq: ITMN ) today announced tha...er and President of InterMune, will present at the...San Francisco on January 15, 2009 at 1:00 p.m.,PST...entation, investors and other,interested parties m...une,s,corporate website at http://www.intermune.c...
...do Biosciences, Inc. announced today that David J....er, will be presenting at the 27th Annual J.P. Mor...Wednesday, January 14, 2009, at 11:30am Pacific Ti...n will include a review of the Company,s lead comp... and enterprise-level business initiatives. , , ...
...AND, New Zealand, Jan. 6 MicroDose Technologies, ...hey have entered into a collaboration to investiga...) technology with MicroDose,s next generation elec...of the agreement, MicroDose will fund the developm...latform and incorporating Nexus6,s SmartinhalerLiv...
Other Biology Technology:MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDose's Electronic Dry Powder Inhaler 2MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDose's Electronic Dry Powder Inhaler 3
(Date:11/23/2009)...ber 16, 2009 -- A USDOE and USDA study concluded t...nd, and cropland pasture could be converted from c..., such as switchgrass, from which biomass could be...cally viable production of a perennial grass monoc...s are removed annually is expected to require nitr...
(Date:11/23/2009)...uthern California biomedical engineer and cardiolo...l to help clinicians distinguish cardiac emergenci...ms manageable with drugs and lifestyle change. , ...o the arteries feeding the heart, offer an inside ...ood vessels, often revealing deposits of a dangero...
(Date:11/23/2009)...tute of General Medical Sciences (NIGMS), part of ...ing $42.3 million for grants in scientific areas i...veloped the GO grant program to stimulate biomedic...y the American Recovery and Reinvestment Act (Reco...romise to have a significant impact on a field of ...
Breaking Biology News(10 mins):Switchgrass produces biomass efficiently 2Stable plaque or heart attack plaque? USC researcher builds new sensor to tell which is which 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema 28MIVI II DME 29 14355 1ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema 28MIVI II DME 29 14355 2ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema 28MIVI II DME 29 14355 3ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema 28MIVI II DME 29 14355 4US HIFU Appoints Arie Belldegrun M D to Board of Directors 5229 1US HIFU Appoints Arie Belldegrun M D to Board of Directors 5229 2US HIFU Appoints Arie Belldegrun M D to Board of Directors 5229 3US Oncology Inc to Exhibit iKnowMed 28TM 29 at the 2009 ASCO EHR Symposium 3A Harnessing the EHR 3A From Incentives to Sustainability 5225 1US Oncology Inc to Exhibit iKnowMed 28TM 29 at the 2009 ASCO EHR Symposium 3A Harnessing the EHR 3A From Incentives to Sustainability 5225 2US Oncology Inc to Exhibit iKnowMed 28TM 29 at the 2009 ASCO EHR Symposium 3A Harnessing the EHR 3A From Incentives to Sustainability 5225 3
...s release is available in German . , , It has a...zation determines the shape of precious stones, bu...How this comes about, has been known for a long ti...tute of Colloids and Interfaces are now whittling ... explain numerous phenomena. The researchers inves...
...s release is available in German . , , A joint ..., Spain) and the Max Planck Institutes of Biochemi...he non-invasive and nanoscale resolved infrared ma...od, which is based on near-field microscopy, opens...f high-performance materials or for contact-free m...
...UMBUS, Ohio) A new strategy developed in the Neon...nwide Children,s Hospital is helping premature inf...ficulties learn to feed on their own. According to...ournal of Pediatric Gastroenterology and Nutrition...o help 15 out of 20 infants with severe feeding di...
Other Biology News:A crystal clear view of chalk formation 2A crystal clear view of chalk formation 3A crystal clear view of chalk formation 4Tension in the nanoworld 2Crib-side studies help struggling newborns go home without feeding tubes 2Crib-side studies help struggling newborns go home without feeding tubes 3
...your samples with eArray and Agilents custom print... create your own microarray designs that meet your...e and receive delivery of your arrays in weeks, an...ray creation application tool that enables you to ...
...utine trace metal analytical lab that require high...se instrumentation. The 7500ce offers unmatched de...ces found in the environmental industry. It is equ...found in the clinical, foods, petrochemical, metal...
Mouse Anti-Polio component type I Monoclonal Antibody, Unconjugated, Clone 9B4 from AntibodyShop A/S
Mouse Anti-Human Choriongonadotropin (hCG) Monoclonal Antibody, Unconjugated, Clone 5F10 from AntibodyShop A/S
Biology Products: